HRAS and plasma cell myeloma: A high KRAS mutation load is detected in other types of cancers, such as multiple myeloma, ovarian, uterine, and stomach cancers (22%, 15%, 18%, and 16%, respectively), whereas NRAS mutations are frequently detected in melanoma (30%), multiple myeloma (18%), acute myelogenous leukemia, colorectal cancer (CRC) (10%), and thyroid cancer (8%), and HRAS is the least frequently mutated RAS gene detected in cancers of the bladder, head, and neck squamous cell carcinomas and the uterus (5% or less) [12].